Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-04-29 9:51 pm Unchanged | 2024-04-25 | 13D | Molecular Templates, Inc. MTEM | Longitude Capital Partners III LLC | 310,052 4.600% | 0 (Unchanged) | Filing History |
| 2023-10-30 5:16 pm Purchase | 2023-10-19 | 13D | Tourmaline Bio, Inc. TRML | Longitude Capital Partners III LLC | 322,077 1.600% | 322,077 (New Position) | Filing History |
| 2023-10-23 5:42 pm Sale | 2023-07-12 | 13D | Molecular Templates, Inc. MTEM | Longitude Capital Partners III LLC | 310,052 5.700% | -1 (-0.00%) | Filing History |
| 2023-08-11 4:08 pm Purchase | 2023-08-01 | 13D | Inozyme Pharma, Inc. INZY | Longitude Capital Partners III LLC | 5,841,045 9.900% | 1,666,666 (+39.93%) | Filing History |
| 2023-02-14 4:24 pm Sale | 2022-12-31 | 13D | Molecular Templates, Inc. MTEM | Longitude Capital Partners III LLC | 310,053 8.000% | -3,544 (-1.13%) | Filing History |
| 2023-02-14 4:18 pm Purchase | 2022-12-31 | 13D | 89bio, Inc. ETNB | Longitude Capital Partners III LLC | 1,233,399 2.600% | 10,666 (+0.87%) | Filing History |
| 2022-05-06 4:33 pm Sale | 2022-04-27 | 13D | Sierra Oncology, Inc. SRRA | Longitude Capital Partners III LLC | 1,485,140 5.700% | -2,140,130 (-59.03%) | Filing History |
| 2022-04-28 4:50 pm Purchase | 2022-04-19 | 13D | Inozyme Pharma, Inc. INZY | Longitude Capital Partners III LLC | 4,174,379 10.400% | 1,355,000 (+48.06%) | Filing History |
| 2022-02-07 5:15 pm Sale | 2022-01-27 | 13D | 89bio, Inc. ETNB | Longitude Capital Partners III LLC | 1,222,733 6.000% | -531,117 (-30.28%) | Filing History |
| 2022-02-04 5:22 pm Purchase | 2022-01-25 | 13D | Sierra Oncology, Inc. SRRA | Longitude Capital Partners III LLC | 3,625,270 17.400% | 175,000 (+5.07%) | Filing History |
| 2021-11-08 07:58 am Purchase | 2021-11-03 | 13D | Sierra Oncology, Inc. SRRA | Longitude Capital Partners III LLC | 3,450,270 20.300% | 1,972,450 (+133.47%) | Filing History |
| 2021-05-21 4:28 pm Purchase | 2021-05-11 | 13D | Talaris Therapeutics, Inc. TALS | Longitude Capital Partners III LLC | 322,078 7.800% | 322,078 (New Position) | Filing History |
| 2021-01-26 5:19 pm Sale | 2020-11-04 | 13D | Axonics, Inc. AXNX | Longitude Capital Partners III LLC | 1,974,692 4.900% | -9,167 (-0.46%) | Filing History |
| 2020-11-25 4:32 pm Sale | 2020-11-16 | 13D | 89bio, Inc. ETNB | Longitude Capital Partners III LLC | 1,753,850 8.800% | -847,027 (-32.57%) | Filing History |
| 2020-08-21 4:24 pm Purchase | 2020-08-11 | 13D | Checkmate Pharmaceuticals, Inc. CMPI | Longitude Capital Partners III LLC | 1,794,671 8.400% | 1,794,671 (New Position) | Filing History |
| 2020-08-20 4:48 pm Sale | 2020-08-10 | 13D | Axonics, Inc. AXNX | Longitude Capital Partners III LLC | 1,983,859 5.000% | -949,474 (-32.37%) | Filing History |
| 2020-08-07 5:21 pm Purchase | 2020-07-28 | 13D | Inozyme Pharma, Inc. INZY | Longitude Capital Partners III LLC | 2,819,379 12.100% | 2,819,379 (New Position) | Filing History |
| 2020-07-20 5:00 pm Purchase | 2020-07-10 | 13D | 89bio, Inc. ETNB | Longitude Capital Partners III LLC | 2,600,877 15.400% | 109,090 (+4.38%) | Filing History |
| 2020-06-05 5:11 pm Sale | 2020-05-26 | 13D | Molecular Templates, Inc. MTEM | Longitude Capital Partners III LLC | 313,597 10.000% | -65,557 (-17.29%) | Filing History |
| 2020-02-10 4:20 pm Purchase | 2020-01-29 | 13D | Sierra Oncology, Inc. SRRA | Longitude Capital Partners III LLC | 1,477,820 14.200% | 1,477,820 (New Position) | Filing History |